Histone deacetylase inhibitors

Advances in Cancer Research

Volumn 91, Issue , 2004, Pages 137-168

  Marks, Paul A ^a   Richon, Victoria M ^b   Miller, Thomas ^b   Kelly, William Kevin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Aton Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXYCINNAMIC ACID BISHYDROXAMIDE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CAPECITABINE; CARBOPLATIN; FR 901228; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LYSINE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PACLITAXEL; PHENYLACETIC ACID; PYROXAMIDE; RETINOIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; APOPTOSIS; APPETITE DISORDER; BONE MARROW TUMOR; BONE PAIN; CANCER; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CHROMATIN STRUCTURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEACETYLATION; DEHYDRATION; DEPRESSION; DIARRHEA; DISORIENTATION; DNA SEQUENCE; DRUG ACTIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; ECG ABNORMALITY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; FATIGUE; FEVER; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC CODE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERAMMONEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; LETHARGY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; NONHUMAN; PARESTHESIA; PERIPHERAL T CELL LYMPHOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN MODIFICATION; REVIEW; SKIN LYMPHOMA; SLURRED SPEECH; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; VOMITING;

EID: 4344688693     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(04)91004-4     Document Type: Article

References (135)

1. Agalioti T., Chen G., Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. Cell. 111:2002;381-392
2. Ardizzoni A., Loprevite M. Histone deacetylation inhibitors. Suppl. Tumori. 1:2002;S52-S54
3. Arts J., de Schepper S., Van Emelen K. Histone deacetylase inhibitors: From chromatin remodeling to experimental cancer therapeutics. Curr. Med. Chem. 10:2003;2343-2350
4. 2+calmodulin inhibits histone deacetylase 5 repressor core binding to myocyte enhancer factor 2. J. Biol. Chem. 278:2003;17625-17635
5. Boivin A.J., Momparler L.F., Hurtubise A., Momparler R.L. Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs. 13:2002;869-874
6. Bouchain G., Delorme D. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: Synthesis and antiproliferative evaluation. Curr. Med. Chem. 10:2003;2359-2372
7. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60:2000;5165-5170
8. Butler L.M., Webb Y., Agus D.B., Higgins B., Tolentino T.R., Kutko M.C., LaQuaglia M.P., Drobnjak M., Cordon-Cardo C., Scher H.I., Breslow R., Richon V.M., Rifkind R.A., Marks P.A. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7:2001;962-970
9. Butler L.M., Zhou X., Xu W. -S., Scher H.I., Rifkind R.A., Marks P.A., Richon V.M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA. 99:2002;11700-11705
10. Carducci M., Bowling M.K., Eisenberger M.A., Sinibaldi V., Chen T., Noe D., Grochow L., Donehower R.C. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res. 17:1997;3972-3973
11. Carducci M.A., Nelson J.B., Chan-Tack K.M., Ayyagari S.R., Sweatt W.H., Campbell P.A., Nelson W.G., Simons J.W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. 2:1996;379-387
12. Chan H.M., Krstic-Demonacos M., Smith L., Demonacos C., La Thangue N.B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat. Cell Biol. 3:2001;667-674
13. Chang S.M., Kuhn J.G., Robins H.I., Schold S.C., Spence A.M., Berger M.S., Mehta M.P., Bozik M.E., Pollack I., Schiff D., Gilbert M., Rankin C., Prados M.D. Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report. J. Clin. Oncol. 17:1999;984-990
14. Choi J.H., Kwon H.J., Yoon B.I., Kim J.H., Han S.U., Joo H.J., Kim D.Y. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 92:2001;1300-1304
15. Coffey D.C., Kutko M.C., Glick R.D., Butler L.M., Heller G., Rifkind R.A., Marks P.A., Richon V.M., La Quaglia M.P. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans-retinoic acid. Cancer Res. 61:2001;3591-3594
16. Colletti S.L., Myers R.W., Darkin-Rattray S.J., Gurnett A.M., Dulski P.M., Galuska S., Allocco J.J., Ayer M.B., Li C., Lim J., Crumley T.M., Cannova C., Schmatz D.M., Wyvratt M.J., Fisher M.H., Meinke P.T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett. 11:2001a;107-111
17. Colletti S.L., Myers R.W., Darkin-Rattray S.J., Gurnett A.M., Dulski P.M., Galuska S., Allocco J.J., Ayer M.B., Li C., Lim J., Crumley T.M., Cannova C., Schmatz D.M., Wyvratt M.J., Fisher M.H., Meinke P.T. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure-activity relationships of apicidin. Part 2. Bioorg. Med. Chem. Lett. 11:2001b;113-117
18. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184:2000;1-16
19. Curtin M., Glaser K. Histone deacetylase inhibitors: The Abbott experience. Curr. Med. Chem. 10:2003;2373-2392
20. Czubryt M.P., McAnally J., Fishman G.I., Olson E.N. Regulation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and mitochondrial function by MEF2 and HDAC5. Proc. Natl. Acad. Sci. USA. 100:2003;1711-1716
21. Dequiedt F., Kasler H., Fischle W., Kiermer V., Weinstein M., Herndier B.G., Verdin E. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity. 18:2003;687-698
22. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J.M., Nusgens B.V., Castronovo V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 21:2002;427-436
23. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 370:2003;737-749
24. Duvic M., Rakhshandra T., Chiao J., Chiao N. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma. Oral presentation at the 45th American Society of Hematology Annual Meeting and Exposition, San Diego, CA, December 6-9, 2003:2003;. see also Blood102, abstract 625
25. Fenrick R., Hiebert S.W. Role of histone deacetylases in acute leukemia. J. Cell. Biochem. Suppl. 30-31:1998;194-202
26. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 401:1999;188-193
27. Fischer D.D., Cai R., Bhatia U., Asselbergs F.A., Song C., Terry R., Trogani N., Widmer R., Atadja P., Cohen D. Isolation and characterization of a novel class II histone deacetylase, HDAC10. J. Biol. Chem. 277:2002;6656-6666
28. Fischle W., Wang Y., Allis C.D. Binary switches and modification cassettes in histone biology and beyond. Nature. 425:2003;475-479
29. Frey R.R., Wada C.K., Garland R.B., Curtin M.L., Michaelides M.R., Li J., Pease L.J., Glaser K.B., Marcotte P.A., Bouska J.J., Murphy S.S., Davidsen S.K. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 12:2002;3443-3447
30. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA. 98:2001;87-92
31. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62:2002;4916-4921
32. Galasinski S.C., Resing K.A., Goodrich J.A., Ahn N.G. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J. Biol. Chem. 277:2002;19618-19626
33. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277:2002;25748-25755
34. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D., Ponder B.A., Kouzarides T., Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24:2000;300-303
35. Gilbert J., Baker S.D., Bowling M.K., Grochow L., Figg W.D., Zabelina Y., Donehower R.C., Carducci M.A. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7:2001a;2292-2300
36. Gilbert J., Baker S.D., Donehower R.C., Herman J.G., Demarzo A., Carducci M. Methyltransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a phase I study of the MT inhibitor, 5-azacytidine and histone deacetylase inhibitor, phenylbutyrate in refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001b;87a
37. Giles R.H., Peters D.J., Breuning M.H. Conjunction dysfunction: CBPp300 in human disease. Trends Genet. 14:1998;178-183
38. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2:2003;151-163
39. Gore S.D., Miller C.B., Weng L.J., Burks K., Griffen C.A., Chen T.L., Smith V., Burke P.J., Grever M., Rowinsky E.K. Clinical development of sodium phenylbutyrate as putative differentiating agent in myeloid malignancies. Anticancer Res. 17:1997;3938a
40. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:2001;6969-6978
41. Gray S.G., Ekstrom T.J. The human histone deacetylase family. Exp. Cell Res. 262:2001;75-83
42. WAF1 involves changes in promoter associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA. 101:2004;1241-1246
43. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA. 100:2003;4389-4394
44. Hauser C., Schuettengruber B., Bartl S., Lagger G., Seiser C. Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation. Mol. Cell. Biol. 22:2002;7820-7830
45. He L.-Z., Tolentino T., Grayson P., Zhong S., Warrell R.P. Jr., Rifkind R.A., Marks P.A., Richon V.M., Pandolfi P.P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108:2001;1321-1330
46. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature. 417:2002;455-458
47. Ishizuka T., Lazar M.A. The N-CoRhistone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol. Cell. Biol. 23:2003;5122-5131
48. Jenuwein T., Allis C.D. Translating the histone code. Science. 293:2001;1074-1080
49. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell. 4:2003;13-18
50. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:2002;415-428
51. Kawai H., Li H., Avraham S., Jiang S., Avraham H.K. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α Int. J. Cancer. 107:2003;353-358
52. Keer H., Reid T., Sreedharan S. Pivanex activity in refractory non-small cell lung cancer, a phase II study. Abstract 314a presented at the 2002 ASCO Annual Meeting, Orlando, FL, May:2001;18-21
53. Kelly W.K., O'Connor O., Richon V.M., Tong W., Rao T., Chiao J., O'Brien J.P., Rifkind R., Marks P.A., Scher H.I., et al. A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor of suberoylanilide hydroxamic acid (SAHA). Presented at the 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 19-22, 2002, Frankfurt, Germany:2002a
54. Kelly W.K., O'Connor O.A., Marks P.A. Histone deacetylase inhibitors: From target to clinical trials. Expert Opin. Invest. Drugs. 11:2002b;1695-1713
55. Kelly W.K., O'Connor O., Richon V., Curley T., Richardson S., Thapi D., Chiao J., Rifkind R., Marks P., Scher H. Phase I clinical trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA). Abstract 226 presented at the 15th AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Boston, MA:2003a
56. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., Scher H. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9:2003b;3578-3588
57. Khochbin S., Verdel A., Lemercier C., Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11:2001;162-166
58. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Chung H.Y., Kim C.W., Kim K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7:2001;437-443
59. Kim Y.B., Lee K.H., Sugita K., Yoshida M., Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene. 18:1999;2461-2470
60. Kimmel K.A., Kindler H.L., Janisch S., Olson E.N., Grove W. Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors. Abstract 345 presented at the 2001 ASCO Annual Meeting, Orlando, FL, May:2001;18-21
61. Komatsu Y., Tomizaki K.Y., Tsukamoto M., Kato T., Nishino N., Sato S., Yamori T., Tsuruo T., Furumai R., Yoshida M., Horinouchi S., Hayashi H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 61:2001;4459-4466
62. Kouzarides T. Acetylation: A regulatory modification to rival phosphorylation? EMBO J. 19:2000;1176-1179
63. Kwon H.J., Kim M.S., Kim M.J., Nakajima H., Kim K.W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer. 97:2002;290-296
64. Kyrylenko S., Kyrylenko O., Suuronen T., Salminen A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell. Mol. Life Sci. 60:2003;1990-1997
65. Lachner M., Jenuwein T. The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14:2002;286-298
66. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T., Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21:2002;2672-2681
67. Lagger G., Doetzlhofer A., Schuettengruber B., Haidweger E., Simboeck E., Tischler J., Chiocca S., Suske G., Rotheneder H., Wintersberger E., Seiser C. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21WAF1CIP1 gene. Mol. Cell. Biol. 23:2003;2669-2679
68. Lehrmann H., Pritchard L.L., Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86:2002;41-65
69. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature. 389:1997;251-260
70. Magnaghi-Jaulin L., Groisman R., Naguibneva I., Robin P., Lorain S., Le Villain J.P., Troalen F., Trouche D., Harel-Bellan A. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 391:1998;601-605
71. Mal A., Harter M.L. MyoD is functionally linked to the silencing of a muscle-specific regulatory gene prior to skeletal myogenesis. Proc. Natl. Acad. Sci. USA. 100:2003;1735-1739
72. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer. 1:2001;194-202
73. Marks P.A., Miller T., Richon V.M. Histone deacetylases. Curr. Opin. Pharmacol. 3:2003;344-351
74. Matsuyama A., Shimazu T., Sumida Y., Saito A., Yoshimatsu Y., Seigneurin-Berny D., Osada H., Komatsu Y., Nishino N., Khochbin S., Horinouchi S., Yoshida M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 21:2002;6820-6831
75. McGraw S., Robert C., Massicotte L., Sirard M.A. Quantification of histone acetyltransferase and histone deacetylase transcripts during early bovine embryo development. Biol. Reprod. 68:2003;383-389
76. McKinsey T.A., Zhang C.L., Olson E.N. Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 11:2001;497-504
77. McKinsey T.A., Zhang C.L., Olson E.N. Signaling chromatin to make muscle. Curr. Opin. Cell Biol. 14:2002;763-772
78. Miller T.A., Witter D.J., Belvedere S. Histone deacetylase inhibitors. J. Med. Chem. 46:2003;5097-5116
79. Murata T., Kurokawa R., Krones A., Tatsumi K., Ishii M., Taki T., Masuno M., Ohashi H., Yanagisawa M., Rosenfeld M.G., Glass C.K., Hayashi Y. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum. Mol. Genet. 10:2001;1071-1076
80. Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., George D.L. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13:1999;2490-2501
81. Neumeister P., Albanese C., Balent B., Greally J., Pestell R. Senescence and epigenetic dysregulation in cancer. Int. J. Biochem. Cell. Biol. 34:2002;1475
82. Olivares J., Williams A., Olson S., Pauer L.R., Grove W. Phase I pharmacokinetic study of CI-994 in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Abstract 346 presented at the 2001 ASCO Annual Meeting, Orlando, FL, May 18-21:2001
83. Petrie K., Guidez F., Howell L., Healy L., Waxman S., Greaves M., Zelent A. The histone deacetylase 9 gene encodes multiple protein isoforms. J. Biol. Chem. 278:2003;16059-16072
84. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:2001;36734-36741
85. Piekarz R.L., Robey R., Bakke S., Sandor V., Wilson W., Bates S. Histone deacetylase inhibitor for the treatment of peripheral or cutaneous T-cell lymphoma. Abstract 2680 presented at the 2001 ASCO Annual Meeting, Orlando, FL, May:2001;18-21
86. Piekarz R.L., Jewell S., Bakke S., Cannon R., Wright J., Bates S. Cardiac effects of depsipeptide, FK228, in patients with T-cell lymphomas. Abstract 806 presented at the 2003 ASCO Annual Meeting, Chicago, IL, May 31-June 3:2003
87. Polevoda B., Sherman F. The diversity of acetylated proteins. Genome Biol. 3:2002
88. Prakash S., Foster B.J., Meyer M., Wozniak A., Heilbrun L.K., Flaherty L., Zalupski M., Radulovic L., Valdivieso M., LoRusso P.M. Chronic oral administration of CI-994: A phase 1 study. Investig. New Drugs. 19:2001;1-11
89. Qiu L., Kelso M.J., Hansen C., West M.L., Fairlie D.P., Parsons P.G. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer. 80:1999;1252-1258
90. Rascle A., Johnston J.A., Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol. Cell. Biol. 23:2003;4162-4173
91. Reddy A., Kaelin W.G. Jr. Using cancer genetics to guide the selection of anticancer drug targets. Curr. Opin. Pharmacol. 2:2002;366-373
92. Remiszewski S.W. The discovery of NVP-LAQ824: From concept to clinic. Curr. Med. Chem. 10:2003;2393-2402
93. Richards E.J., Elgin S.C. Epigenetic codes for heterochromatin formation and silencing: Rounding up the usual suspects. Cell. 108:2002;489-500
94. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R.A., Marks P.A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA. 93:1996;5705-5708
95. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA. 95:1998;3003-3007
96. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA. 97:2000;10014-10019
97. Ryan Q.C., Headlee D.J., Sparreboom A., Figg W.D., Zhai S., Trepel J.B., Murgo A., Elsayed Y., Karp J.E., Sausville E.A. A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. Abstract 802 presented at the 2003 ASCO Annual Meeting, Chicago, IL, May 31-June 3:2003
98. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA. 96:1999;4592-4597
99. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., Brooks R., Piekarz R.L., Tucker E., Figg W.D., Chan K.K., Goldspiel B., Fojo A.T., Balcerzak S.P., Bates S.E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8:2002;718-728
100. Schuettengruber B., Simboeck E., Khier H., Seiser C. Autoregulation of mouse histone deacetylase 1 expression. Mol. Cell. Biol. 23:2003;6993-7004
101. Singh S.B., Zink D.L., Liesch J.M., Mosley R.T., Dombrowski A.W., Bills G.F., Darkin-Rattray S.J., Schmatz D.M., Goetz M.A. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal α-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem. 67:2002;815-825
102. Skov S., Rieneck K., Bovin L.F., Skak K., Tomra S., Michelsen B.K., Odum N. Histone deacetylase inhibitors: A new class of immunosuppressors targeting a novel signal-pathway essential for CD154 expression. Blood. 101:2003;1430-1438
103. Smirnov D.A., Hou S., Ricciardi R.P. Association of histone deacetylase with COUP-TF in tumorigenic Ad12-transformed cells and its potential role in shut-off of MHC class I transcription. Virology. 268:2000;319-328
104. Spotswood H.T., Turner B.M. An increasingly complex code. J. Clin. Invest. 110:2002;577-582
105. Su G.H., Sohn T.A., Ryu B., Kern S.E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60:2000;3137-3142
106. Thibault A., Cooper M.R., Figg W.D., Venzon D.J., Sartor A.O., Tompkins A.C., Weinberger M.S., Headlee D.J., McCall N.A., Samid D., et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 54:1994;1690-1694
107. Thibault A., Samid D., Cooper M.R., Figg W.D., Tompkins A.C., Patronas N., Headlee D.J., Kohler D.R., Venzon D.J., Myers C.E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 75:1995;2932-2938
108. Timmermann S., Lehrmann H., Polesskaya A., Harel-Bellan A. Histone acetylation and disease. Cell. Mol. Life Sci. 58:2001;728-736
109. Toh Y., Yamamoto M., Endo K., Ikeda Y., Baba H., Kohnoe S., Yonemasu H., Hachitanda Y., Okamura T., Sugimachi K. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol. Rep. 10:2003;333-338
110. Tong J.J., Liu J., Bertos N.R., Yang X.J. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res. 30:2002;1114-1123
111. Trojer P., Brandtner E.M., Brosch G., Loidl P., Galehr J., Linzmaier R., Haas H., Mair K., Tribus M., Graessle S. Histone deacetylases in fungi: Novel members, new facts. Nucleic Acids Res. 31:2003;3971-3981
112. Tsai S.C., Seto E. Regulation of histone deacetylase 2 by protein kinase CK2. J. Biol. Chem. 277:2002;31826-31833
113. Urnov F.D., Yee J., Sachs L., Collingwood T.N., Bauer A., Beug H., Shi Y.B., Wolffe A.P. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway. EMBO J. 19:2000;4074-4090
114. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expr. 5:1996;245-254
115. Voelter-Mahlknecht S., Mahlknecht U. Cloning and structural characterization of the human histone deacetylase 6 gene. Int. J. Mol. Med. 12:2003;87-93
116. Vrana J.A., Decker R.H., Johnson C.R., Wang Z., Jarvis W.D., Richon V.M., Ehinger M., Fisher P.B., Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 18:1999;7016-7025
117. Wang C., Fu M., Mani S., Wadler S., Senderowicz A.M., Pestell R.G. Histone acetylation and the cell-cycle in cancer. Front. Biosci. 6:2001;D610-D629
118. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoRmSin3HDAC1 complex. Proc. Natl. Acad. Sci. USA. 95:1998;10860-10865
119. Warrell R.P. Jr., He L.Z., Richon V., Calleja E., Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90:1998;1621-1625
120. Warrener R., Beamish H., Burgess A., Waterhouse N.J., Giles N., Fairlie D., Gabrielli B. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17:2003;1550-1552
121. Waterborg J.H. Dynamics of histone acetylation in vivo: A function for acetylation turnover? Biochem. Cell Biol. 80:2002;363-378
122. Wen Y.D., Cress W.D., Roy A.L., Seto E. Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I. J. Biol. Chem. 278:2002;1841-1847
123. Wisinski K.B. A phase I study of an oral histone deacetylase inhibitor, MS-275 in patients with refractory solid tumors and lymphomas. Proc. Am. Soc. Clin. Oncol. 2003;87a
124. Wolffe A.P., Pruss D. Deviant nucleosomes: The functional specialization of chromatin. Trends Genet. 12:1996;58-62
125. Wozniak A., O'Shaughnessy J., Fiorica J., Grove W. Phase II trial of CI-994 in patients with advanced nonsmall cell lung cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;487a
126. Yamagoe S., Kanno T., Kanno Y., Sasaki S., Siegel R.M., Lenardo M.J., Humphrey G., Wang Y., Nakatani Y., Howard B.H., Ozato K. Interaction of histone acetylases and deacetylases in vivo. Mol. Cell. Biol. 23:2003;1025-1033
127. Yarden R.I., Brody L.C. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. USA. 96:1999;4983-4988
128. Yoon H.G., Chan D.W., Huang Z.Q., Li J., Fondell J.D., Qin J., Wong J. Purification and functional characterization of the human N-CoR complex: The roles of HDAC3, TBL1 and TBLR1. EMBO J. 22:2003;1336-1346
129. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265:1990;17174-17179
130. Yoshida M., Matsuyama A., Komatsu Y., Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. 10:2003;2351-2358
131. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., Schrump D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94:2002;504-513
132. Zhang Y., Reinberg D. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev. 15:2001;2343-2360
133. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22:2003;1168-1179
134. Zhou D.C., Kim S.H., Ding W., Schultz C., Warrell R.P. Jr., Gallagher R.E. Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans-retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 99:2002;1356-1363
135. Zhou X., Richon V.M., Wang A.H., Yang X.J., Rifkind R.A., Marks P.A. Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. Proc. Natl. Acad. Sci. USA. 97:2000;14329-14333